What caused the drop in HPC.AX stock today?

The decline to A$0.005 was driven by heavy selling and a volume spike to 1,672,013 shares. Thin liquidity, negative operating cash flow, and lack of fresh positive news likely amplified the move.

What is the Meyka AI forecast for HPC.AX stock?

Meyka AI's forecast model projects about **A$0.007** over 12 months, implying roughly **40.00%** upside from **A$0.005** today. Forecasts are model-based projections and not guarantees.

Is HPC.AX stock a buy after the drop?

Meyka AI gives a **B+ (73.18)** score with a BUY suggestion but highlights mixed fundamentals and liquidity risk. Size positions carefully and wait for clearer cash flow or revenue improvements.

Where can I find updates and trade data for HPC.AX stock?

Monitor ASX trade feeds and company releases, review the Meyka stock page for live data, and check trusted market sources for relevant sector news and distribution updates.

AU Stocks

HPC.AX falls 16.67% to A$0.005 on ASX: liquidity and valuation risks ahead

ByHuzaifa Zahoor January 15, 2026January 15, 2026

HPC.AX stock plunged 16.67% to A$0.005 at market close on 15 Jan 2026 on the ASX, driven by a surge in selling volume. Trading volume hit 1,672,013 shares, more than double the 726,685 average, suggesting forced exits or short-term profit taking. The Hydration Pharmaceuticals Company Limited (HPC.AX) shows stretched valuation metrics and a small market cap of A$2,154,005, heightening downside risk for small-cap traders in the Consumer Defensive sector. We examine why the stock is among today’s top losers and what traders should watch next.